Data Insights

IMC-002 by ImmuneOncia Therapeutics for Solid Tumor: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Solid Tumor

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Lymphoma: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Lymphoma

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Triple-Negative Breast Cancer (TNBC)

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Marginal Zone B-cell Lymphoma

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Metastatic Biliary Tract Cancer: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Metastatic Biliary Tract Cancer

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Follicular Lymphoma: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Follicular Lymphoma

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Mantle Cell Lymphoma

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Diffuse Large B-Cell Lymphoma

Data Insights

IMC-002 by ImmuneOncia Therapeutics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

IMC-002 by Suzhou Immunofoco Biotechnology for Gastric Cancer: Likelihood of Approval

IMC-002 is under clinical development by Suzhou Immunofoco Biotechnology and currently in Phase I for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Gastric Cancer